Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

1 hr ago | Dallas Morning News

Jim Landers: $1,000-per-pill cure is difficult to swallow

Gilead's drug Sovaldi, combined with other drugs in pill form, has cured more than 15,000 cases of hepatitis C. In a 12-week regimen, it has a success rate of more than 80 percent.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Social Solutions, Express Scripts, Texas, Opinion

5 hrs ago | SFGate

In Europe, two drugs will compete to treat rare blood cancer

In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned.

Comment?

Related Topix: Medicine, Cancer, Health, Leukemia, Biotech, Startups, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Pharmacyclics

7 hrs ago | Seeking Alpha

Why Merck Is Heading To $65

Management has not lost focus. Merck has a plan to attack and grow its share in immuno-oncologyand entering/dominating the hepatitis C and vaccines market.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Hepatitis, Johnson and Johnson

11 hrs ago | TheStreet.com

Why Gilead Sciences (GILD) Stock Is Up Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Mozilla, Science / Technology, TheStreet, Financial Markets

11 hrs ago | TheStreet.com

Why Gilead Sciences (GILD) Stock Is Up Today

The company's new price target represents 41% upside from its opening price today.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Science / Technology, Financial Markets

14 hrs ago | BioSpace

Politicizing Gilead Sciences, Inc.'s R&D Solvadi Costs Is A Reckless And Dangerous Misadventure

Gilead has become the whipping boy du jour for the forthcoming Obamacare-driven cost explosion in government and private health spending.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

14 hrs ago | Daily Policy Digest

Legal Battles Rage over Hepatitis-C Drugs

The Wall Street Journal reports Hepatitis-C drug sales could amount to $20 billion annually by 2020, sparking an intense legal battle among the world's biggest pharmaceutical companies.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Sat Jul 26, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Le CMUH europen adopte une opinion positive envers le Zydelig de Gilead pour le traitement de la leucmie lymphode chronique et du lymphome folliculaire )--Gilead Sciences, Inc. a annoncA© aujourd'hui que le ComitA© des mA©dicaments A usage humain , le comitA© scientifique de l'Agence europA©e... )--Gilead Sciences, Inc.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Food and Drug Administration

The Motley Fool

This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark

With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Science / Technology, Startups, Gilead Sciences, CGI Pharmaceuticals, Healthcare Law, Food and Drug Administration, Law

Medical News

EGPAF applauds new licensing agreement to improve access to HIV medication for children

The Elizabeth Glaser Pediatric AIDS Foundation applauds the new licensing agreement between the Medicines Patent Pool and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate , a promising new HIV medication.

Comment?

Related Topix: HIV/AIDS, Health, Biotech, Medicine, Healthcare Industry, Australia, World News,

Fri Jul 25, 2014

The Washington Post

Why Sovaldi took off: Previous treatments were terrible

In a story Thursday, I dove into the societal implications of the new $84,000 hepatitis C treatment.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Healthcare Industry, Healthcare Law, Law, World News

Forbes.com

Politicizing Gilead's Research And Development Costs For Sovaldi ...

Gilead has become the whipping boy du jour for the forthcoming Obamacare-driven cost explosion in government and private health spending.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Insurance

South China Morning Post

Despite huge profits, Gilead Sciences defends price of its hepatitis drug

Champagne corks were doubtless popping in the California headquarters of Gilead Sciences on Thursday as its quarterly earnings were announced.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Opinion

JD Supra

Gilead Sciences, Inc. v. Natco Pharma Ltd.

Case Name: Gilead Sciences, Inc. v. Natco Pharma Ltd. , 2013-1418, 2014 U.S. App.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Tamiflu, Oseltamivir (generic), Inventions, Science / Technology

Q-Notes

Science and Society: Let's Fight HIV and Hep C Together

Scientists and community members have striven to make their points and find common ground on this last full day of the XX International AIDS Conference on Thursday.

Comment?

Related Topix: HIV/AIDS, Health, Hepatitis, Medicine, Biotech, Healthcare Industry, Startups, Gilead Sciences, Food and Drug Administration, Prison

Investor's Business Daily

European CHMP Adopts Positive Opinion for Gilead's Zydelig ...

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorization Application for ZydeligA , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Marketing, Leukemia, Health, Lymphoma, Opinion

The Washington Post

U.S. Index Futures Gain After S&P 500 Record as Facebook Climbs

U.S. stock-index futures advanced, signaling the Standard & Poor's 500 Index will extend a record, as companies from Facebook Inc. to Gilead Sciences Inc. posted financial results that beat analysts' estimates.

Comment?

Related Topix: Startups, Facebook, Social Software, Biotech, Medicine, Healthcare Industry, Qualcomm, Travel/Tourism, TripAdvisor, Financial Markets

Thu Jul 24, 2014

USA Today

Barrage of companies reporting earnings today

On Wall Street, it's not necessarily how much a company earns that always counts, but how well it does compared to what everyone expects.

Comment?

Related Topix: Financial Markets, Beverages, PepsiCo, Biotech, Medicine, Healthcare Industry

Fox News

U.S. Futures Rise as Ford, Facebook Tick Higher

Stock futures rose on Thursday as well-received earnings lifted shares of Facebook Inc. and Ford Motor Co.

Comment?

Related Topix: Housing, Biotech, Medicine, Healthcare Industry, Business News

Seeking Alpha

Understanding The Excitement That Surrounds Gilead

Gilead is changing the way we view viral diseases. The company produces the most successful treatments for Hepatitis C, and the two most common first-line treatments for HIV.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Healthcare Law, Law, Food and Drug Administration

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••